AMAL Therapeutics SA announces the appointment of Dr. Thomas Bogenrieder as Chief Clinical Officer

Geneva - 25 June 2020 - AMAL Therapeutics is very happy to welcome Thomas Bogenrieder, MD, PhD, as Chief Clinical Officer as of July 1, 2020. Thomas will join AMAL’s operations in Geneva. In this new role, he will focus on AMAL’s preclinical and clinical research activities especially in the vaccine and oncolytic virus areas, to support and promote BI’s Cancer Immunology and Immune Modulation unit and interface closely with BI’s Oncology Medical organization to advance and integrate the concepts in the overall portfolio.